Efficacy and effects of dasatinib/staxacil

Dasatinib (Dasatinib) is an oral second-generation tyrosine kinase inhibitor (TKI) developed by Bristol-Myers Squibb in the United States. It is mainly used to treat Philadelphia chromosome-positive leukemia (Ph+). It plays an important role in the precise treatment of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). It is another key targeted drug after imatinib. Dasatinib was first approved by the US FDA in 2006 and was subsequently launched in Europe, Japan, Canada and other countries. It has now become one of the standard regimens for the treatment of CML worldwide.

In terms of mechanism, dasatinib effectively inhibits the tyrosine kinase activity ofBCR-ABL fusion protein, fundamentally blocking the abnormal signaling of leukemia cells, thereby inhibiting their proliferation and inducing apoptosis. Compared with first-generation TKIs (such as imatinib), dasatinib can not only inhibit BCR-ABL wild-type, but also effectively act on multiple drug-resistant mutants, such as most mutations except T315I. At the same time, dasatinib can also target signaling pathways such as Src family kinases (SFKs), c-KIT and PDGFR, thereby demonstrating more comprehensive anti-tumor activity in the complex tumor microenvironment. This multi-target feature enables it to not only delay disease progression in clinical practice, but also help some patients achieve deep molecular remission (DMR), laying the foundation for subsequent drug reduction or discontinuation.

In terms of indications, dasatinib has a wide range of applications. It is used for newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic phase CML; for CML patients who are resistant or intolerant to first-generation drugs such as imatinib (whether in the chronic phase, accelerated phase or myeloid/lymphoblastic phase), dasatinib can be used as a second-line or even third-line treatment option. In addition, the drug is also suitable for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), especially those who have failed to respond to previous chemotherapy or targeted drugs. In the pediatric field, dasatinib is suitable for children 1 year old and above with chronic phase Ph+ CML, as well as pediatric patients newly diagnosed with Ph+ ALL combined with chemotherapy, providing new treatment hope for young patient groups.

In terms of actual efficacy, dasatinib usually takes effect quickly, and some patients can observe hematological or cytogenetic responses in the early stages of treatment. Multiple international studies have shown that long-term use can significantly extend progression-free survival (PFS) and overall survival (OS). Its high efficiency stems from the rapid penetration and strong binding ability of the drug within cells, which can maintain sustained inhibitory effects at lower doses. At the same time, dasatinib has strong central nervous system penetration, giving it a unique therapeutic advantage in patients with leukemic meningeal infiltration, which is not available in some other TKI drugs.

Although dasatinib has significant efficacy, individual differences still need to be paid attention to during medication. Some patients may experience side effects such as bone marrow suppression, fluid retention, pleural effusion, or decreased platelets, which can usually be improved by adjusting the dose or discontinuing the drug for a short period of time. Doctors will regularly evaluate efficacy and safety based on the patient's disease status, tolerance and testing indicators. It is worth noting that you should avoid taking strong acid inhibitors or grapefruit-like foods at the same time during medication to avoid affecting drug absorption and metabolism.

Overall, dasatinib is a targeted anti-cancer drug with both high efficiency and broad spectrum, and represents an advanced direction in precision treatment of leukemia. Whether it is achieving deep remissions in treatment-naïve patients or providing new treatment options in drug-resistant patients, Startaxel has demonstrated lasting clinical value.

Reference materials:https://go.drugbank.com/drugs/DB01254